CY1121465T1 - Μεθοδοι και συνθεσεις για τη θεραπεια της φλεγμονωδους νοσου του εντερου - Google Patents
Μεθοδοι και συνθεσεις για τη θεραπεια της φλεγμονωδους νοσου του εντερουInfo
- Publication number
- CY1121465T1 CY1121465T1 CY20181101409T CY181101409T CY1121465T1 CY 1121465 T1 CY1121465 T1 CY 1121465T1 CY 20181101409 T CY20181101409 T CY 20181101409T CY 181101409 T CY181101409 T CY 181101409T CY 1121465 T1 CY1121465 T1 CY 1121465T1
- Authority
- CY
- Cyprus
- Prior art keywords
- treatment
- compositions
- disease
- inflammative
- methods
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000002757 inflammatory effect Effects 0.000 title 1
- ZWBTYMGEBZUQTK-PVLSIAFMSA-N [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,32-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-1'-(2-methylpropyl)-6,23-dioxospiro[8,33-dioxa-24,27,29-triazapentacyclo[23.6.1.14,7.05,31.026,30]tritriaconta-1(32),2,4,9,19,21,24,26,30-nonaene-28,4'-piperidine]-13-yl] acetate Chemical compound CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c4NC5(CCN(CC(C)C)CC5)N=c4c(=NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C ZWBTYMGEBZUQTK-PVLSIAFMSA-N 0.000 abstract 2
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 abstract 2
- 229960002626 clarithromycin Drugs 0.000 abstract 2
- WDQPAMHFFCXSNU-BGABXYSRSA-N clofazimine Chemical compound C12=CC=CC=C2N=C2C=C(NC=3C=CC(Cl)=CC=3)C(=N/C(C)C)/C=C2N1C1=CC=C(Cl)C=C1 WDQPAMHFFCXSNU-BGABXYSRSA-N 0.000 abstract 2
- 229960004287 clofazimine Drugs 0.000 abstract 2
- 229960000885 rifabutin Drugs 0.000 abstract 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6514408P | 2008-02-08 | 2008-02-08 | |
| PCT/AU2009/000129 WO2009097651A1 (en) | 2008-02-08 | 2009-02-05 | Methods and compositions for treating inflammatory bowel disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1121465T1 true CY1121465T1 (el) | 2020-05-29 |
Family
ID=40951740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20181101409T CY1121465T1 (el) | 2008-02-08 | 2018-12-28 | Μεθοδοι και συνθεσεις για τη θεραπεια της φλεγμονωδους νοσου του εντερου |
Country Status (18)
| Country | Link |
|---|---|
| US (10) | US8343511B2 (https=) |
| EP (2) | EP3391882A1 (https=) |
| JP (1) | JP5572872B2 (https=) |
| AU (1) | AU2009212097B2 (https=) |
| CA (1) | CA2714043C (https=) |
| CY (1) | CY1121465T1 (https=) |
| DK (1) | DK2247291T3 (https=) |
| ES (1) | ES2708087T3 (https=) |
| HR (1) | HRP20190045T1 (https=) |
| HU (1) | HUE041305T2 (https=) |
| IL (1) | IL207420A (https=) |
| NZ (1) | NZ587250A (https=) |
| PL (1) | PL2247291T3 (https=) |
| PT (1) | PT2247291T (https=) |
| SI (1) | SI2247291T1 (https=) |
| TR (1) | TR201819940T4 (https=) |
| WO (1) | WO2009097651A1 (https=) |
| ZA (1) | ZA201005735B (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2247291T (pt) | 2008-02-08 | 2019-02-01 | Red Hill Biopharma Ltd | Métodos e composições para tratamento de doença inflamatória do intestino |
| TWI573590B (zh) * | 2011-09-20 | 2017-03-11 | 雷希爾生藥有限公司 | 治療自體免疫疾病之組成物及方法 |
| US20150017673A1 (en) | 2012-08-30 | 2015-01-15 | James Sacchettini | Compositions and methods for drug-sensitization or inhibition of a cancer cell |
| WO2015123392A1 (en) * | 2014-02-14 | 2015-08-20 | The Texas A&M University System | Compositions and methods for inhibition of angiogenesis and lymphangiogenesis |
| EP3145510B8 (en) * | 2014-05-22 | 2021-10-27 | Kuenstner, John, Todd | Treatment of diseases using combination of ultraviolet blood irradiation and antibiotics |
| WO2016178240A1 (en) * | 2015-05-04 | 2016-11-10 | Gufic Biosciences Limited | A freeze dried pharmaceutical formulation of rifabutin and process for preparation thereof |
| WO2017060771A2 (en) | 2015-10-06 | 2017-04-13 | Redhill Biopharma Ltd. | Combination therapies for treating cancer |
| CN107202848B (zh) * | 2017-07-24 | 2022-11-15 | 浙江华海药业股份有限公司 | 一种氯法齐明的液相色谱分析方法 |
| US11321665B2 (en) * | 2017-08-29 | 2022-05-03 | Weightrx Inc. | System and method of automated tracking of consumable products |
| US11351158B2 (en) * | 2019-09-12 | 2022-06-07 | BioVersys AG | Rifabutin treatment methods, uses, and compositions |
| WO2022003421A2 (en) * | 2020-06-30 | 2022-01-06 | Redhill Biopharma Ltd. | Triple antibiotic fixed-dose combination products, dosing regimen, methods, and kits for treating pulmonary non-tuberculosis mycobacterial infections |
| US20240230666A1 (en) * | 2021-03-25 | 2024-07-11 | The Regents Of The University Of Michigan | Compositions and methods for detecting, preventing, and treating disturbed microbiota-immune homeostasis |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5840733A (en) | 1996-07-01 | 1998-11-24 | Redcell, Canada, Inc. | Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes |
| EP0971735B1 (en) * | 1997-04-01 | 2008-03-19 | Thomas Julius Borody | Methods and compositions for treating inflammatory bowel disease |
| US6761903B2 (en) * | 1999-06-30 | 2004-07-13 | Lipocine, Inc. | Clear oil-containing pharmaceutical compositions containing a therapeutic agent |
| PT2247291T (pt) | 2008-02-08 | 2019-02-01 | Red Hill Biopharma Ltd | Métodos e composições para tratamento de doença inflamatória do intestino |
-
2009
- 2009-02-05 PT PT09708397T patent/PT2247291T/pt unknown
- 2009-02-05 DK DK09708397.6T patent/DK2247291T3/en active
- 2009-02-05 PL PL09708397T patent/PL2247291T3/pl unknown
- 2009-02-05 ES ES09708397T patent/ES2708087T3/es active Active
- 2009-02-05 JP JP2010545328A patent/JP5572872B2/ja active Active
- 2009-02-05 HR HRP20190045TT patent/HRP20190045T1/hr unknown
- 2009-02-05 SI SI200931923T patent/SI2247291T1/sl unknown
- 2009-02-05 HU HUE09708397A patent/HUE041305T2/hu unknown
- 2009-02-05 EP EP18171416.3A patent/EP3391882A1/en not_active Withdrawn
- 2009-02-05 EP EP09708397.6A patent/EP2247291B1/en active Active
- 2009-02-05 NZ NZ587250A patent/NZ587250A/en unknown
- 2009-02-05 AU AU2009212097A patent/AU2009212097B2/en active Active
- 2009-02-05 TR TR2018/19940T patent/TR201819940T4/tr unknown
- 2009-02-05 CA CA2714043A patent/CA2714043C/en active Active
- 2009-02-05 US US12/918,310 patent/US8343511B2/en active Active
- 2009-02-05 WO PCT/AU2009/000129 patent/WO2009097651A1/en not_active Ceased
-
2010
- 2010-08-04 IL IL207420A patent/IL207420A/en active IP Right Grant
- 2010-08-11 ZA ZA2010/05735A patent/ZA201005735B/en unknown
-
2012
- 2012-12-20 US US13/722,395 patent/US9072763B2/en active Active
-
2014
- 2014-05-07 US US14/271,814 patent/US9314477B2/en active Active
- 2014-05-07 US US14/271,758 patent/US9198926B2/en active Active
-
2016
- 2016-04-18 US US15/131,533 patent/US20160228464A1/en not_active Abandoned
-
2017
- 2017-05-03 US US15/585,879 patent/US10105379B2/en active Active
-
2018
- 2018-01-02 US US15/860,298 patent/US10143702B2/en active Active
- 2018-10-29 US US16/173,530 patent/US10434114B2/en active Active
- 2018-12-28 CY CY20181101409T patent/CY1121465T1/el unknown
-
2019
- 2019-08-28 US US16/554,201 patent/US10765691B2/en active Active
-
2020
- 2020-03-12 US US16/816,759 patent/US11090326B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1121465T1 (el) | Μεθοδοι και συνθεσεις για τη θεραπεια της φλεγμονωδους νοσου του εντερου | |
| CY1124928T1 (el) | Αναστολεις πυραζολυλο κινοξαλινο κινασης | |
| CY1120941T1 (el) | Παραγωγα φαινυλοτριαζολιου υποκατεστημενα με υδροξυαλκυλιο και χρησεις αυτων | |
| CY1124144T1 (el) | Συνθεσεις και μεθοδοι για θεραπεια εγκεφαλικου επεισοδιου σε ενα υποκειμενο επι ταυτοχρονης θεραπειας στατινης | |
| CY1122966T1 (el) | 5-βρωμο-2,6-δι-(1η-πυραζολ-1-υλ)πυριμιδιν-4-αμινη για χρηση στη θεραπευτικη αγωγη καρκινου | |
| CY1113882T1 (el) | Φαρμακευτικες συνθεσεις κυκλοσπορινης (cyclosporin) | |
| CY1125274T1 (el) | Μεθοδοι για την θεραπεια συνθηκων που σχετιζονται με την ενεργοποιηση συμπληρωματικου εξαρτωμενου απο την masp-2 | |
| CY1114820T1 (el) | Νεες ανοσοενισχυτικες ενωσεις βασιζομενες σε φλαγκελλινη και χρηση αυτων | |
| CY1118695T1 (el) | Αναστολεις απομεθυλασων ιστονων | |
| CY1115751T1 (el) | Φαρμακευτικος συνδυασμος 3-(3-διμεθυλαμινο-1-αιθυλ-2-μεθυλπροπυλ)-φαινολης και ενος αντιεπιληπτικου | |
| EA201300242A1 (ru) | Фармацевтические композиции, содержащие замещенные ациланилиды | |
| CY1120318T1 (el) | Υποκατεστημενες βενζυλινδαζολες για χρηση ως αναστολεις κινασης bub1 στη θεραπευτικη αντιμετωπιση υπερπολλαπλασιαστικων ασθενειων | |
| CY1119167T1 (el) | Αναστολεις toy nkcc για τη θεραπεια του αυτισμου | |
| CY1114397T1 (el) | Φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν βακτηρια τα οποια μειωνουν οξαλικα | |
| CY1118611T1 (el) | Συνδυασμοι που περιεχουν παραγωγα της 6-βενζυλο-φαινυλο-2-θειοτετραϋδροπυραν-3,4,5-τριολης ως αναστολεις των συμμεταφορεων 1 και 2 νατριου-γλυκοζης για να χρησιμοποιηθουν σε διαβητικους ασθενεις | |
| CL2011000691A1 (es) | Compuestos derivados de nicotinamida sustituida; composicion farmaceutica que los comprende; uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias. | |
| CL2008003798A1 (es) | Compuestos derivados de heterobiciclos aromaticos sustituidos, inhibidores de pi3 quinasa; composicion farmaceutica; utiles en el tratamiento de cancer, melanomas, glioblastomas, entre otras enfermedades. | |
| DE602006015431D1 (de) | Chemische verbindungen | |
| CY1107440T1 (el) | Ενωσεις αρυλουριας εν συνδυασμω με αλλα κυτταροστατικα ή κυτταροτοξικα μεσα για τη θεραπεια ανθρωπινων καρκινων | |
| CY1113640T1 (el) | Μεθοδοι για την θεραπευτικη αγωγη ρευματοειδους αρθριτιδας | |
| CY1113482T1 (el) | Αναστολεις υποδοχεα σιγμα | |
| CY1115381T1 (el) | Διενυδρη υδροχλωρικη ναλμεφαινη | |
| CL2008000202A1 (es) | Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor. | |
| CY1110190T1 (el) | Παραγωγα πιπεραζινυλιου χρησιμα στην αγωγη των νοσων στις οποιες μεσολαβει ο υποδοχεας gpr38 | |
| EA201170441A1 (ru) | Терапевтические противовирусные пептиды |